In a strategic move, Kindeva Drug Delivery has successfully acquired Summit Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in intranasal drug delivery. The acquisition, from its original family shareholders, amplifies Kindeva's established capabilities by introducing a novel drug delivery platform. This expansion positions Kindeva to cater to a broader spectrum of complex drug-device combination products, including pulmonary, injectable, transdermal, and nasal solutions, thereby strengthening its commitment to serving biopharma customers.
Summit Biosciences, with a legacy dating back to 2009, has been a pioneer in the unit dose nasal spray market, showcasing a remarkable history of innovation. The addition of Summit to Kindeva's portfolio is expected to foster greater advancements in drug delivery.
Augmenting its global manufacturing footprint, Kindeva incorporates Summit's 55,000-square-foot cGMP facility located in Lexington, Kentucky. This facility, approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), boasts specialized laboratories and integrated manufacturing operations. With a strong track record in bringing intranasal medicines to market, the facility aligns seamlessly with Kindeva's mission of delivering high-quality pharmaceutical solutions.
This acquisition signifies a significant milestone for Kindeva Drug Delivery, further solidifying its position as a leader in the pharmaceutical outsourcing landscape.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!